Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemed Corporation filings document a Delaware operating company whose capital stock trades on the NYSE under CHE and whose business is conducted through VITAS Healthcare and Roto-Rooter. Current reports disclose segment operating results for hospice and palliative care services, plumbing and drain cleaning services, patient-care metrics, service revenue and capital allocation.
Chemed's regulatory record also includes 8-K disclosures for earnings releases, Regulation FD updates, senior secured revolving credit facilities and related direct financial obligations. Proxy materials cover director elections, executive compensation, pay-versus-performance data and governance matters, while event reports record leadership changes within the VITAS business.
Chemed Corporation (NYSE: CHE) filed a Form 8-K on June 27, 2025 to furnish a Regulation FD disclosure.
- Material event: The Company issued a press release (Exhibit 99) stating it now expects second-quarter 2025 earnings to be lower than previously anticipated and is reducing its full-year 2025 earnings guidance.
- The filing does not include specific dollar amounts, revised EPS figures or updated revenue ranges; only the direction of the change is disclosed.
- No other operational changes, financings, or acquisitions were reported in the filing.
- The press release itself is furnished, not filed, preserving safe-harbor protections for forward-looking statements.
Because the Company is signalling weaker performance and a downward revision to outlook, the disclosure is materially negative for investors, implying potential pressure on near-term financial results and valuation multiples. Investors will need to review the full press release and forthcoming Q2 results to quantify the impact.